Technique Developed to Trigger Immunity to Various STDs

Researchers have designed a unique method for inducing immunity to Chlamydia trachomatis infection. The findings could accelerate progress toward the development of a vaccine against C. trachomatis infections, which can lead to reproductive dysfunction and extreme local inflammation requiring medical care.

C. trachomatis is the most common bacterial pathogen of sexually transmitted disease (STD), accounting for more than a million reported infections in the United States alone yearly.

Researchers from the California NanoSystems Institute (CNSI) at the University of California, Los Angeles (UCLA; USA) and the David Geffen School of Medicine at UCLA have developed the new method. The study, which entailed the first use of a novel vaccine platform that utilizes an engineered nanoparticle delivery system, appeared in the April 30, 2009, issue of the online journal PLoS ONE, published by the [U.S.] Public Library of Science. The investigators, a partnership between UCLA immunologists and nanotechnologists, was led by Dr. Kathleen Kelly, an associate professor of pathology and laboratory medicine and a CNSI member, and Dr. Leonard H. Rome, interim director of the CNSI and a UCLA professor of biologic chemistry.

The researchers were able to find an unexpected link between vault nanoparticles and mucosal immunity. Vaults are barrel-shaped nanoscale capsules found in the cytoplasm of all mammalian cells, which can be engineered to act as potential therapeutic delivery devices. "The primary goal of vaccines is to generate robust cell-mediated immune responses at mucosal surfaces while reducing overall inflammation caused by infection,” Dr. Kelly said. "We found that vault nanoparticles containing immunogenic proteins can act as ‘smart adjuvants' for inducing protective immunity at mucosal surfaces while avoiding destructive inflammation.”

Adjuvants are molecular triggers that initiate vaccine responses. Mucosal immune responses provide superior protection against disease, but there are currently no adjuvants approved by the U.S. Food and Drug Administration that are capable of stimulating cell-mediated immune responses within mucosal tissues. Mucosal surfaces are hostile environments, and immunogenic proteins require added protection for delivery to cells in order to induce immunity.

The researchers produced recombinant vaults through a process that involved the molecular engineering of these naturally occurring cellular structures to test the concept that vaults can have a broad nanosystems application as malleable nanocapsules. "Our research team wanted to find out if recombinant vaults could provide such protection by encapsulating an antigen and preserving its functional characteristics, even within the cells,” Dr. Kelly commented.

The internal cavity of the recombinant vault nanoparticle is large enough to hold multiple immunogenic proteins, and because vaults are the size of small microbes, a vault particle containing such proteins can be easily absorbed by the targeted cells. Vaults are being studied for use in the delivery of a variety of potential therapeutics, including synthetic and natural compounds, nucleic acids, and proteins. Recombinant vaults containing proteins are easily produced, making vaults a feasible vaccine delivery platform.

"Adjuvants provide the necessary assistance to vaccine preparations for promoting immunity or protection from infection by combining the vault with a part of the Chlamydia organism,” Dr. Kelly stated. "We were able to design a vaccine that prevented Chlamydia infection better than other designs.”

The research team found that when they immunized female mice with recombinant vaults containing a component of Chlamydia and then exposed the mice to a vaginal challenge with live Chlamydia, their reproductive tracts were protected from severe bacterial infection. The results suggest that vaults are superior adjuvants for immunization against infections largely limited to mucosal tissues. "We are encouraged that our findings could accelerate progress toward developing a vaccine to guard against this infection,” Dr. Kelly said.

The California NanoSystems Institute is an integrated research center operating jointly at UCLA and UC Santa Barbara whose mission is to foster interdisciplinary collaborations for discoveries in nanosystems and nanotechnology; train a next generation of scientists, educators, and technology leaders; and facilitate partnerships with industry.

Related Links:
California NanoSystems Institute